June 9, 2017
Vertex Pharmaceuticals welcomes new independent board member
Vertex Pharmaceuticals has appointed Alan M. Garber, M.D., Ph.D. as an independent member of its board of directors.
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Vertex Pharmaceuticals
June 1, 2017
Vertex has good news for 500 Irish patients with cystic fibrosis
Vertex Pharmaceuticals Incorporated has reached an agreement with the Health Service Executive (HSE) in the Republic of Ireland to fund Orkambi (lumacaftor/ivacaftor).
May 19, 2017
FDA expands Kalydeco indication for cystic fibrosis
The U.S. Food and Drug Administration (FDA) expanded the approved indication for Vertex Pharmaceuticals’ Kalydeco (ivacaftor) for the treatment of cystic fibrosis (CF).
May 18, 2017
FDA OK’s Vertex’s cystic fibrosis drug
U.S. Food and Drug Administration (FDA) has approved Vertex Pharmaceuticals’ Kalydeco (ivacaftor) for use in people with cystic fibrosis (CF) ages 2 and older who have one of 23 residual function mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
March 22, 2017
Galapagos nets $7.5 million from partner for reaching milestone in a study
Galapagos NV has reached a milestone in a Phase 1 study for cystic fibrosis, it is conducting with its partner AbbVie, …
December 19, 2016
Vertex announces German reimbursement agreement for its cystic fibrosis drug
Vertex Pharmaceuticals Incorporated has reached a pricing and reimbursement agreement for Orkambi (lumacaftor/ivacaftor) with the German Federal Association of the…
November 7, 2016
Vertex's Phase 3 cystic fibrosis drug study shows improvement
Vertex Pharmaceuticals Incorporated today announced the results of a Phase 3 study of Orkambi (lumacaftor/ivacaftor) in children with cystic fibrosis…
November 23, 2015
Pfizer’s ex man joins Vertex as Vice President and Chief Legal Officer
Vertex Pharmaceuticals, a biotechnology company has appointed Pfizer’s Senior Vice president Michael J. Parini to the role of Executive Vice President and Chief Legal Officer.